New influenza variant is surging, however vaccination nonetheless our greatest guess: WHO | EUROtoday

Influenza and different respiratory viruses are surging, Dr Wenqing Zhang, Unit Head for Global Respiratory Threats on the Department of Epidemic and Pandemic Threats Management of the World Health Organization (WHO) advised reporters in Geneva, and this 12 months is marked by “the emergence and the rapid expansion of a new AH3N2 virus subclade”.

The new variant – known as J.2.4.1 or subclade Ok – was first famous in August in Australia and New Zealand and has since been detected in over 30 nations, she stated.

DNA shape-shifter

“Current epidemiological data do not indicate an increase in disease severity, although this genetic shift makes a notable evolution in the virus,” Dr Zhang stated.

Influenza viruses are continually evolving, she defined, which is why the influenza vaccine composition is often up to date.

“WHO tracks these changes, assesses associated risks to public health and makes vaccine composition recommendations twice a year, through a longstanding global system – the Global Influenza Surveillance and Response System (GISRS), in collaboration with other global experts,” Dr. Zhang stated.

The new variant (has not been included into?) shouldn’t be a part of the composition of the newest vaccines produced for the Northern Hemisphere influenza season, the WHO professional defined.

Still, “early evidence suggests that current seasonal vaccines continue to offer protection against severe diseases and reduce the risk of hospital hospitalization,” she stated.

WHO estimates that there are round one billion instances of seasonal influenza yearly, together with as much as 5 million instances of extreme respiratory sickness. Up to 650 000 deaths annually are owing to seasonal influenza-related respiratory illness.

Risk-reduction recommendation

“Vaccination remains our most effective defence, including against drifted strains, particularly for high-risk populations and those taking care of them,” Dr Zhang insisted.

The WHO professional shared the outcomes of an early estimation of the vaccine’s effectiveness in opposition to the brand new variant, printed within the United Kingdom some weeks in the past.

“It’s quite promising,” she stated, pointing to the info which confirmed that the vaccine is round 75 per cent efficient in opposition to extreme illness and hospitalization in kids and round 35 per cent amongst adults.

Dr Zhang warned that the upcoming vacation season could deliver an extra surge in respiratory diseases. “Advanced planning and preparedness efforts, including encouraging vaccination uptake and strengthening health system readiness, are strongly recommended,” she stated.

The WHO professional suggested nations to strengthen lab diagnostics and 12 months‑spherical illness surveillance and to take part within the WHO GISRS surveillance community.

Global monitoring stays key

The community includes influenza centres in 130 nations in addition to a dozen reference laboratories.

Asked about whether or not the United States will stay a member of the community subsequent 12 months regardless of the nation’s choice to go away WHO, efficient 22 January 2026, Dr Zhang stated that “from the flu perspective, from the respiratory surveillance and preparedness perspective, certainly we would need all the countries in the world to participate in the surveillance, preparedness and a response for influenza and other respiratory viruses because we don’t know the next pandemic strain, when and where it would emerge”.

“And that time between the emergence and being picked up and characterized and put into vaccines…it would make a lot of difference with regards to the number of lives that could be saved,” she concluded.